EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 58.9% from a year ago
Other current liabilities stood at $8.89M at the end of Q1 FY2026, up 58.9% from a year earlier and down 46.7% from the prior quarter. Over 3 fiscal years it compounded at +20.6% a year.
Context
- Other current liabilities amounted to 3.1% of total assets at the end of Q1 FY2026, up 1.5 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +58.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.67M USD
- Year-over-year change
- +25.7%
- 4-year CAGR
- +22.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.67M | +25.7% |
| FY2024 | 2024-12-31 | 13.27M | -0.1% |
| FY2023 | 2023-12-31 | 13.28M | +39.5% |
| FY2022 | 2022-12-31 | 9.52M | +30.0% |
| FY2021 | 2021-12-31 | 7.32M | — |
Other Current Liabilities vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's Mar 2026 other current liabilities of $8.89M is the 5th highest of the 11 companies compared; the peer median is $4.54M.
- Its year-over-year change of +58.9% is the 4th highest of 10, against a peer median of +22.8%.
- Other current liabilities amounts to 3.1% of total assets for EYPT, versus a peer median of 1.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $34.76M | +384.6% | +29.5% | 5.3% | |
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $32.01M | +1810.0% | — | 5.8% |
SEPNSepterna, Inc. | Sep 2026 | $26.4M | -57.2% | +51.2% | 4.3% |
| Aug 2026 | $22.23M | +22.8% | +37.3% | 1.9% | |
| Mar 2026 | $8.89M | +58.9% | +20.6% | 3.1% | |
| Mar 2026 | $4.74M | -6.6% | +52.2% | 1.6% | |
| Mar 2026 | $4.34M | -37.1% | +9.0% | 1.5% | |
| Mar 2026 | $2.8M | +168.4% | — | 2.2% | |
| Mar 2026 | $1.54M | +50.5% | — | 0.7% | |
| Sep 2026 | $0 | — | -22.3% | 0.0% | |
| Sep 2026 | $0 | -100.0% | +0.6% | 0.0% | |
| Peer median (excluding EYPT) | $4.54M | +22.8% | +29.5% | 1.7% | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 178.59M | 95.63M | 281.26M | 99.7M | 101.82M |
| Short-term Investments | 32.97M | 48.93M | 49.79M | 271.21M | 204.27M |
| Net Receivables | 18.35M | 15.5M | 805K | 607K | 651K |
| Inventory | 3.62M | 2.89M | 3.91M | 2.31M | 1.81M |
| Other Current Assets | 517K | 782K | 1.01M | 1.41M | 20.11M |
| Total Current Assets | 237.75M | 172.81M | 344.8M | 383.31M | 328.66M |
| Property, Plant & Equipment (Net) | 2.73M | 7.4M | 10.23M | 29.18M | 20.22M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 22.75M | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 150K | 150K | 150K | 5.98M | 15.12M |
| Total Non-current Assets | 25.63M | 7.55M | 10.38M | 35.16M | 35.34M |
| Total Assets | 263.37M | 180.36M | 355.18M | 418.47M | 364M |
| Account Payables | 7.39M | 5.92M | 6.5M | 11.72M | 10.49M |
| Short-term Debt | 0 | 10.48M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.07M | 1.21M | 38.59M | 17.78M | 0 |
| Other Current Liabilities | 7.32M | 9.52M | 13.28M | 13.27M | 16.67M |
| Total Current Liabilities | 23.66M | 34.54M | 63.26M | 49.05M | 37.02M |
| Long-term Debt | 36.56M | 29.31M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 14.56M | 13.56M | 20.69M | 10.85M | 0 |
| Other Non-current Liabilities | 2.35M | 600K | 0 | 205K | 87K |
| Total Non-current Liabilities | 55.33M | 49.45M | 25.6M | 32.92M | 20.86M |
| Total Liabilities | 78.99M | 83.99M | 88.86M | 81.96M | 57.88M |
| Common Stock | 34K | 34K | 49K | 68K | 83K |
| Retained Earnings | (569.1M) | (671.35M) | (742.15M) | (873.02M) | (1.1B) |
| Accumulated OCI | 841K | 786K | 864K | 1.03M | 961K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 184.38M | 96.37M | 266.32M | 336.5M | 306.11M |
| Total Debt | 39.2M | 46.35M | 4.91M | 21.86M | 20.77M |
| Net Debt | (139.39M) | (49.29M) | (276.36M) | (77.85M) | (81.05M) |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.